. Author manuscript; available in PMC: 2013 Apr 1.

Published in final edited form as: Arthritis Rheum. 2012 Feb 10;64(4):1263–1271. doi: 10.1002/art.34348

Table 3.

Crude and standardized rates of probable and highly probable incident malignancies for the study cohorts. All rates are standardized to the age, sex, and race distribution of the “all children with JIA” cohort.

Cohort	Probable and Highly Probable Incident Malignancies		Highly Probable Incident Malignancies Only
Cohort	Crude Rate per 100K person-years (95% CI)	Standardized Rate	Crude Rate per 100K person-years (95% CI)	Standardized Rate
All children with JIA	55.4 (26.4–116.3)	55.4	31.7 (11.9–84.4)	31.7
JIA unexposed	88.2 (36.7–211.8)	89.6	52.9 (17.1–163.9)	59.3
JIA MTX without TNF inhibitor	51.3 (12.8–205.0)	52.1	25.6 (3.6–181.9)	22.5
JIA any TNF inhibitor	0 (0–126.0)	(zero)	0 (0–126.0)	(zero)
Asthma	17.9 (15.0–21.4)	16.5	13.5 (11.0–16.5)	12.3
ADHD	11.2 (8.4–15.1)	13.0	8.9 (6.4–12.4)	9.7
SEER external control		15.0		15.0

JIA = juvenile idiopathic arthritis; ADHD = attention-deficit hyperactivity disorder; MTX = methotrexate or leflunomide; TNF inhibitor = etanercept, infliximab, or adalimumab; SEER = Surveillance Epidemiology and End Results